Live Breaking News & Updates on Ret Fusion

Stay updated with breaking news from Ret fusion. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

The Role of Molecular Diagnostics in Real-World DTC Management

Daniel Bowles, MD, explores the role of molecular testing in driving treatment decisions and its application in the initial diagnosis stage, while also discussing driver mutations, primary surgeries, and the importance of high-quality DNA and RNA, highlighting the 2-year window for durable RNA sequencing. ....

Optimizing Therapy , Molecular Diagnostics , Gene Fusion , Ret Fusion , Alk Fusion , Next Generation Sequencing , Single Gene Testing , Panel Testing , Braf 600e ,

Exploring Incidence and Histology of Differentiated Thyroid Cancer

Marcia Brose, MD, delivers a comprehensive overview of differentiated thyroid cancer, detailing the incidence rates, histological features, genetic profiles, and phenotypic characteristics associated with this malignancy, providing valuable insights into the complex nature of the disease. ....

Optimizing Therapy , Differentiated Thyroid Cancer , Thyroid Nodules , Autopsy Series , Thyroid Cancer , Unnecessary Surgery , Hurthle Cell , Braf Mutation , Gene Fusion , Ret Fusion ,

Lessons from LIBRETTO-431 Trial in RET+ NSCLC

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC. ....

Patrick Forde , Post Conference Perspectives , Non Squamous Disease , Ret Targeted , Ret Fusion , Oncogene Subtypes , Ret Fusion Positive Nsclc , Platinum Doublet Chemotherapy , Targeted Therapy , Libretto 431 , Ntrk Fusions , Non Squamous Lung Cancer ,

COMING SOON: Randomized Phase 3 Study of First-Line Selpercatinib Versus Pembrolizumab and Chemotherapy in RET Fusion-Positive Non-Small Cell Lung Cancer

Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023. ....

Randomized Phase , First Line Selpercatinib Versus Pembrolizumab , Positive Non Small Cell Lung Cancer , Non Small Cell Lung Cancer , Lung Cancer , Ret Fusion , Ret Mutation , Ret Positive , Chemo Io , Loxo 292 , Esmo 2023 , Esmo Annual Meeting , Novel Therapy , Targeted Therapy ,

Retevmo Improves Progression-Free Survival in Patients with RET-Fusion Positive NSCLC

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer. ....

Herberth Loong , Chinese University Of Hong Kong , Department Of Clinical Oncology , Phasei Clinical Trials Centre , East Asian , Non East Asia , Clinical Oncology , Chinese University , Ret Fusion , Non Small Cell Lung Cancer ,